TABLE 2.
Comparison between losartan and hydrochlorothiazide vs. losartan and amlodipine groups in the reduction of the study parameters at week 20
| Losartan and HCTZ (n = 72) | Losartan and amlodipine (n = 70) | Pa | |
| Clinic SBP (mmHg) | 15.2 ± 15.0 | 14.9 ± 13.7 | 0.9003 |
| Clinic DBP (mmHg) | 7.8 ± 8.0 | 9.2 ± 7.5 | 0.2833 |
| Brachial SBP, 24 h (mmHg) | 6.5 ± 1.2 | 9.9 ± 1.2 | 0.0449 |
| Brachial SBP, daytime (mmHg) | 7.0 ± 1.3 | 10.8 ± 1.3 | 0.0429 |
| Brachial SBP, night-time (mmHg) | 5.5 ± 1.3 | 8.4 ± 1.3 | 0.1264 |
| Central SBP, 24 h (mmHg) | 6.4 ± 1.1 | 9.2 ± 1.1 | 0.0738 |
| Central SBP, daytime (mmHg) | 6.8 ± 1.2 | 9.6 ± 1.1 | 0.0836 |
| Central SBP, night-time (mmHg) | 4.9 ± 1.3 | 8.3 ± 1.3 | 0.0613 |
| Ambulatory AIx75, 24-h (%) | −0.4 ± 0.6 | 1.1 ± 0.6 | 0.0955 |
| Ambulatory AIx75, daytime (%) | 0.1 ± 0.7 | 1.6 ± 0.7 | 0.1296 |
| Ambulatory AIx75, night-time (%) | −1.2 ± 1.0 | 0.4 ± 1.0 | 0.2705 |
| Ambulatory cfPWV, 24-h (m/s) | 0.15 ± 0.05 | 0.27 ± 0.05 | 0.0507 |
| Ambulatory cfPWV, daytime (m/s) | 0.16 ± 0.05 | 0.28 ± 0.05 | 0.0808 |
| Ambulatory cfPWV, night-time (m/s) | 0.09 ± 0.05 | 0.26 ± 0.05 | 0.0235 |
| Albumin creatinine ratio (mg/g) | 8.27 ± 2.43 | 10.56 ± 2.45 | 0.5100 |
| Fasting blood glucose (mg/dl) | −7.04 ± 1.99 | −2.63 ± 1.97 | 0.1487 |
| Uric acid (mg/dl) | −0.38 ± 0.11 | 0.19 ± 0.11 | 0.0002 |
AIx75, augmentation index calibrated for the assumed ambulatory heart rate of 75 beats per minute; cfPWV, carotid femoral pulse wave velocity; HCTZ, dihydrochlorothiazide.
aAdjusted for baseline difference and additionally adjusted for SBPs at baseline and at week 20 in case of AIx and cfPWV. Mean ± standard error.